Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 5:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Low Dose Psilocybin Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators

NCT02145091
View directory record Official record
Conditions
Healthy
Interventions
Moderately-high dose of psilocybin, Moderately-low dose of psilocybin, Very-low dose of psilocybin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
25 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 29, 2019 · Synced Sep 8, 2026, 5:24 PM EDT
Withdrawn Phase 2 Interventional

Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder

NCT06005662
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 8, 2026, 5:24 PM EDT
Not yet recruiting Phase 2 Interventional

Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids

NCT06827054
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Functional Magnetic Resonance Imaging, Interview, Psilocybine, Psychotherapy, Questionnaire Administration
Procedure · Other · Drug + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 8, 2026, 5:24 PM EDT
Recruiting Phase 2 Interventional

The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

NCT07610369
View directory record Official record
Conditions
Depression, Parkinson's Disease (PD)
Interventions
Psilocybin (drug)
Drug
Lead sponsor
Yale University
Other
Eligibility
40 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 8, 2026, 5:24 PM EDT
Recruiting Phase 1 Interventional

Psilocybin in Chronic Low Back Pain and Depression

NCT06355414
View directory record Official record
Conditions
Chronic Low-back Pain, Depression
Interventions
Psilocybin, Methylphenidate
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 8, 2026, 5:24 PM EDT
Recruiting Phase 2 Interventional

Wellcome Leap Psilocybin for OUD

NCT06786325
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Anna Rose Childress, Ph.D.
Other
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 8, 2026, 5:24 PM EDT
Recruiting Phase 2 Interventional

Psilocybin Therapy for Depression in Parkinson's Disease

NCT06455293
View directory record Official record
Conditions
Parkinson Disease, Depression
Interventions
Psilocybin, Pimavanserin
Drug
Lead sponsor
Joshua Woolley, MD, PhD
Other
Eligibility
40 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 8, 2026, 5:24 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder

NCT07499583
View directory record Official record
Conditions
Treatment Resistant Depression, Substance Use Disorders
Interventions
Psilocybin
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 8, 2026, 5:24 PM EDT
Recruiting Phase 2 Interventional

Psilocybin rTMS for Treatment Resistant Depression

NCT06132178
View directory record Official record
Conditions
Treatment Resistant Depression, MDD, Major Depressive Disorder, Recurrent Depression, Depression
Interventions
Psilocybin, Accelerated intermittent theta burst (aiTBS) rTMS treatment, Low-dose psilocybin, Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment
Drug · Device
Lead sponsor
University of Texas at Austin
Other
Eligibility
22 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 8, 2026, 5:24 PM EDT
Not yet recruiting Phase 2 Interventional

Psilocybin Therapy for Methamphetamine Use Disorder and HIV

NCT07756736
View directory record Official record
Conditions
Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV)
Interventions
Psilocybin 5 mg, Psilocybin 25 mg, Motivational Support
Drug · Behavioral
Lead sponsor
Nicky Mehtani, MD, MPH
Other
Eligibility
25 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 8, 2026, 5:24 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Exploratory Study of Low Dose Psilocybin

NCT05227742
View directory record Official record
Conditions
Demoralization
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
25 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 8, 2026, 5:24 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain

NCT07306364
View directory record Official record
Conditions
Chronic Low Back Pain (CLBP), Physical Therapy, Psilocybin
Interventions
Psilocybin 10 mg, Psilocybin 25 mg, Niacin 100 mg
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 8, 2026, 5:24 PM EDT
Completed Phase 1 Interventional

Psilocybin for the Treatment of Migraine Headache

NCT03341689
View directory record Official record
Conditions
Migraine Headache
Interventions
High Dose Psilocybin, Low Dose Psilocybin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Sep 8, 2026, 5:24 PM EDT
Active, not recruiting No phase listed Observational

Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism

NCT07189988
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
psilocybin
Other
Lead sponsor
Healing Advocacy Fund
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 8, 2026, 5:24 PM EDT
Completed Phase 1 Interventional

Psilocybin for the Treatment of Cluster Headache

NCT02981173
View directory record Official record
Conditions
Cluster Headache
Interventions
0.143 mg/kg Psilocybin or 10 mg Psilocybin, 0.0143 mg/kg Psilocybin or 1 mg Psilocybin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Sep 8, 2026, 5:24 PM EDT
Completed Phase 1 Interventional

Psilocybin for Treatment of Obsessive Compulsive Disorder

NCT03300947
View directory record Official record
Conditions
Obsessive-compulsive Disorder (OCD)
Interventions
Psilocybin 100 mcg/kg, Psilocybin 300 mcg/kg, Lorazepam 1 mg
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Sep 8, 2026, 5:24 PM EDT
Recruiting Phase 2 Interventional

Pragmatic Trial of Psilocybin Therapy in Palliative Care

NCT05403086
View directory record Official record
Conditions
Demoralization
Interventions
Psilocybin, Ketamine
Drug
Lead sponsor
Charles S. Grob, M.D.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Greenbrae, California • Los Angeles, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 8, 2026, 5:24 PM EDT
Recruiting Phase 2 Interventional

State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma

NCT06888128
View directory record Official record
Conditions
PTSD
Interventions
Psilocybin 15mg, Psilocybin 25mg
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 8, 2026, 5:24 PM EDT
Recruiting Phase 1Phase 2 Interventional

Psilocybin to Treat Depression in Spinal Cord Injury

NCT07251491
View directory record Official record
Conditions
Spinal Cord Injury, Depression - Major Depressive Disorder, Veteran
Interventions
Psilocybin (Usona Institute)
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 8, 2026, 5:24 PM EDT
Not yet recruiting Phase 2 Interventional

Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder

NCT07296094
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 8, 2026, 5:24 PM EDT
Recruiting Phase 2 Interventional

Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder

NCT06067737
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 8, 2026, 5:24 PM EDT
Recruiting Phase 2 Interventional

Psilocybin on Brain Mechanisms of Motivation in OUD

NCT06810310
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Psilocybin (high dose), psilocybin (low dose)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 8, 2026, 5:24 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Psychedelics in Healthy Older Adults With Low Well-being

NCT07386730
View directory record Official record
Conditions
Anhedonia in Healthy Volunteers, Older Adults (50-90 Years)
Interventions
Psilocybin (drug), Dextromethorphan (DXM)
Drug
Lead sponsor
Jennifer Mitchell
Other
Eligibility
50 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 8, 2026, 5:24 PM EDT
Active, not recruiting Phase 1 Interventional

Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder

NCT03554174
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Low Dose Psilocybin, Placebo, Medium Dose Psilocybin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 8, 2026, 5:24 PM EDT